Sra-333
Healthy Subjects
Wyeth is now a wholly owned subsidiary of PfizerPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
4 Active assets in the Healthy Subjects cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Keppra UCB Pharma | Phase 4 | BB |
Letrozole Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | CC |
Voriconazole OrsoBio, Inc | Phase 1 | CC |
RIFALDAZINE OrsoBio, Inc | Phase 1 | CC |
Omeprazole OrsoBio, Inc | Phase 1 | CC |
Same molecule, other indications
Sra-333 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →